As­traZeneca's can­cer com­bo wins sec­ond nod in one month, this time in lung can­cer

Weeks af­ter cel­e­brat­ing the first can­cer win for its Imfinzi and Imju­do duo, As­traZeneca is once again break­ing out the par­ty hats.

The mon­o­clon­al an­ti­body com­bo scored a la­bel ex­pan­sion on Thurs­day in metasta­t­ic non-small cell lung can­cer (NSCLC) along­side plat­inum-based chemother­a­py. Just last month, the drugs won a nod in un­re­sectable he­pa­to­cel­lu­lar car­ci­no­ma (HCC), the most com­mon type of liv­er can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER